PLAU/uPA (active form)[Biotin], His & Avi, Human
PLAU/uPA (active Form)[Biotin], His & Avi, Human

Immobilized Human Upar, hFc Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for PLAU/uPA (active form)[Biotin], His & Avi, Human, His Tag with the EC50 of 21.5ng/ml determined by ELISA.

PLAU/uPA (active Form)[Biotin], His & Avi, Human

The purity of PLAU/uPA (active form)[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

PLAU/uPA (active Form)[Biotin], His & Avi, Human

PLAU/uPA (active form)[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

PLAU/uPA (active form)[Biotin], His & Avi, Human

Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.
Z04587
¥123,118.00

Ask us a question
Product Introduction
Species Human
Protein Construction
PLAU/uPA [Ser21-Leu431, which consists of two chains: Long chain A (Ser21-Phe177) and chain B(Ile179-Leu 431). The long chain A is further cleaved to yield a short chain A (Lys156-Phe 177) and N-Terminus fragment (Ser21-Lys155)]
Accession # P00749-1		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per ug by the LAL method.
Biological Activity Measured by its ability to cleave a peptide substrate, N-carbobenzyloxy-Gly-Gly-Arg-7-amido-4-methylcoumarin(Z-GGR-AMC). Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 49.3 kDa
Apparent Molecular Weight Due to protein lysis and glycosylation, the protein migrates to 24-26 kDa(long chain A), 35-38 kDa(chain B) and 52-60 kDa(long chain A&chain B) based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • PLAU/uPA (active Form)[Biotin], His & Avi, Human
    • PLAU/uPA (active Form)[Biotin], His & Avi, Human

    Immobilized Human Upar, hFc Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for PLAU/uPA (active form)[Biotin], His & Avi, Human, His Tag with the EC50 of 21.5ng/ml determined by ELISA.

  • PLAU/uPA (active Form)[Biotin], His & Avi, Human
    • PLAU/uPA (active Form)[Biotin], His & Avi, Human

    The purity of PLAU/uPA (active form)[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • PLAU/uPA (active Form)[Biotin], His & Avi, Human
    • PLAU/uPA (active Form)[Biotin], His & Avi, Human

    PLAU/uPA (active form)[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.
Synonyms PLAU; Urokinase; ATF; UPA; URK; u-PA; BDPLT5; QPD

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.